Circulating surfactant protein-D and the risk of cardiovascular morbidity and mortality.

TitleCirculating surfactant protein-D and the risk of cardiovascular morbidity and mortality.
Publication TypeJournal Article
Year of Publication2011
AuthorsHill, J, Heslop, C, Man, SFPaul, Frohlich, J, Connett, JE, Anthonisen, NR, Wise, RA, Tashkin, DP, Sin, DD
JournalEur Heart J
Volume32
Issue15
Pagination1918-25
Date Published2011 Aug
ISSN1522-9645
KeywordsAdult, Biological Markers, Cardiovascular Diseases, Chronic Disease, Cohort Studies, Female, Hospitalization, Humans, Interleukin-6, Male, Middle Aged, Pneumonia, Prognosis, Pulmonary Surfactant-Associated Protein D, Risk Factors, ROC Curve
Abstract

AIMS: Surfactant protein-D (SP-D) is a lung-specific protein that is detectable in human plasma. We determined the relationship of circulating SP-D to cardiovascular disease (CVD) and total mortality in subjects with and without CVD.

METHODS AND RESULTS: Plasma SP-D levels were measured in 806 patients who underwent coronary angiography to assess its predictive value for cardiovascular mortality. Serum SP-D levels were also measured in a replication cohort to assess its relationship with CVD events in 4468 ex- and current smokers without a known history of coronary artery disease (CAD). Patients who died during follow-up had significantly higher plasma SP-D levels than those who survived (median 85.4 vs. 64.8 ng/mL; P < 0.0001). Those in the highest quintile of SP-D had 4.4-fold higher risk of CVD mortality than those in the lowest quintile (P < 0.0001) independent of age, sex, and plasma lipid levels. In a group of current and ex-smokers without a known history of CAD, serum SP-D levels were elevated in those who died or were hospitalized for CVD compared with those who did not (median 99.8 vs. 90.6 ng/mL; P = 0.0001).

CONCLUSION: Circulating SP-D is a good predictor of cardiovascular morbidity and mortality and adds prognostic information to well-established risk factors such as age, sex, and plasma lipids and is a promising biomarker to link lung inflammation/injury to CVD.

DOI10.1093/eurheartj/ehr124
Alternate JournalEur. Heart J.
PubMed ID21653561
Grant List / / Canadian Institutes of Health Research / Canada